Novo Nordisk

Eli Lilly's Mounjaro sales dip as semaglutide generics flood Indian market

Mounjaro sales in March dropped to ₹114 crore ($12.3 million) in March from ₹135 crore a month earlier, Pharmarack data show

As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices

Drugmaker cuts prices of injectable semaglutide brands to expand access in India, but says no similar price reduction is planned for oral semaglutide brand Rybelsus

Delhi HC directs unsold Olymviq doses to govt hospitals after 30 days

Court allows Dr Reddy's 30 days to clear stock, after which unsold Olymviq doses will be supplied to government hospitals in presence of Novo Nordisk representative

Ozempic trademark clash forces DRL to offer rebranding of Olymviq as Olymra

Dr Reddy's told the Delhi High Court it plans to rebrand its diabetes drug amid a trademark dispute with Novo Nordisk over similarity with its drug Ozempic

Sun Pharma, Dr Reddy's, Glenmark launch generic semaglutide in India

Indian pharma majors Sun Pharma, Dr Reddy's and Glenmark on Saturday announced the launch of their generic versions of semaglutide injection used for diabetes and weight management following the molecule behind products like Ozempic and Wegovy going off patent in India. The prices of the generic versions of semaglutide injection are considerably lower than the prices of the innovator, Novo Nordisk. Sun Pharmaceutical Industries launched its semaglutide injection under the brand names Noveltreat and Sematrinity in India, in all strengths. Noveltreat is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity and is available in five dose strengths -- 0.25 mg/0.5 ml, 0.5 mg/0.5 ml, 1 mg/0.5 ml, 1.7 mg/0.75 ml, and 2.4 mg/0.75 ml, Sun Pharma said in a statement. Sematrinity is indicated for treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise and is available in t

Ozempic copies set to crash to $14 in India as generic GLP-1 era starts

Natco Pharma Ltd. plans to sell an injection for semaglutide, the active ingredient in both Ozempic and Wegovy - with prices starting from ₹1,290

Bracing for a flood of semaglutide generics, Novo holds the price line

Novo Nordisk says competition in semaglutide will be driven by science and quality, not pricing, as multiple generic versions prepare to enter India after patent expiry

Delhi High Court allows Dr Reddy's to make semaglutide for export

The Delhi High Court has upheld an order permitting Dr Reddy's Laboratories to manufacture semaglutide in India solely for export, rejecting Novo Nordisk's appeal in the ongoing patent dispute

Novo Nordisk, Abbott tie up to launch second Ozempic brand in India

Abbott will commercialise Extensior, a second semaglutide brand of Ozempic in India, as part of Novo Nordisk's strategy to expand access amid rising demand and looming patent expiry

Sun Pharma receives regulatory approval to sell generic Wegovy in India

Sun Pharma said it will launch generic semaglutide in India after the patent expiry in March 2026, becoming the second domestic drugmaker to secure regulatory approval for the blockbuster drug

Popular weight-loss drugs shouldn't carry suicide warnings, FDA says

Federal regulators have told drugmakers Novo Nordisk and Eli Lilly to remove label warnings about potential suicidal thoughts and behaviours from their blockbuster weight-loss medications. The US Food and Drug Administration on Tuesday said a comprehensive review found no increased risk related to suicide among users of the GLP-1 drugs for obesity, including Novo Nordisk's Wegovy and Saxenda and Eli Lilly's Zepbound. A preliminary review in January 2024 showed no link between the drugs and suicidal thought or actions, the FDA said. At that time, however, officials said they could not rule out that a small risk may exist. The new analysis puts those concerns to rest. Labeling for other drugs known as GLP-1 receptor agonists approved to treat diabetes carried no such warnings, the agency noted. Today's FDA action will ensure consistent messaging across the labelling for all FDA-approved GLP-1 RA medications, officials said.

US FDA asks drugmakers to drop suicide warnings on weight-loss drugs

The FDA had reached similar conclusion following a preliminary review in 2024, but had acknowledged at the time that it could not rule out a small risk because of limited data

HC seeks Novo's response on Natco Pharma plea to revoke semaglutide patent

The patent in question is due to lapse in March next year. The court is scheduled to take up Natco's challenge for further hearing in February

Semaglutide patent loss to create ₹5,000 crore opportunity: Report

Patent expiries of blockbuster weight-loss drug semaglutide may create a ₹5,000 crore generic opportunity for Indian pharma firms across India and key emerging and regulated markets

Eli Lilly, Novo Nordisk compete for lead in India's obesity drug market

Novo's strategy emphasises price cuts and accelerated launches, while Lilly's products benefitted from hitting the market early

Novo Nordisk secures US FDA approval for first weight-loss pill

US-listed shares of Novo jumped 8 per cent and Lilly fell 1 per cent in extended trading after the approval announcement

Novo gets US nod for Wegovy pill, eyes January launch in obesity market

Novo will start selling the pill, the first of the blockbuster GLP-1 class, in the US in early January, the company said in a statement Monday

With an eye on rivals, Novo Nordisk launches diabetes drug Ozempic in India

With Mounjaro gaining ground, launch comes just three months before Novo loses patent for semaglutide

Novo Nordisk challenges HC order permitting Dr Reddy's semaglutide exports

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

Delhi HC refuses to halt order allowing Dr Reddy's to export Semaglutide

The Delhi High Court refused to stop an earlier order that lets Dr Reddy's make Semaglutide in India only for export, saying Novo Nordisk's patent challenge needs a full hearing before any decision